The Use of DPP-4 Inhibitors in Short Bowel Syndrome

Phase 4 Terminated 8 enrolled Stanley Dudrick's Memorial Hospital

RandomizedSingle-groupOpen-labelTreatment

Summary

The inhibition of Dipeptidyl peptidase-4 should increase the concentration of glucagone-like peptide 1 and 2, and the increase of the latter should increase the absorptive capacity of the intestine.

Timeline

Start: 2016-01
Primary completion: 2020-04
Completion: 2020-04

Outcome

Outcome not reported

Stopped: “too many side-effects”

Publications

Background Jeppesen PB. Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome. JPEN J Parenter Enteral Nutr. 2014 May;38(1 Suppl):45S-52S. doi: 10.1177/0148607114526241. Epub 2014 Mar 10.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sitagliptin	Small molecule	—	Oral